Are 5-HT3antagonists effective in obsessive-compulsive disorder? A systematic review of literature

Antidepressant and anti-anxiety like effects of 4i (N-(3-chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist in acute and chronic neurobehavioral rodent models

(2014) Deepali Gupta et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder

(2014) Mariana Pizarro et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder

(2014) Mahnaz Heidari et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Venlafaxine extended-release treatment of hoarding disorder

(2014) Sanjaya Saxena et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Diagnostic subtyping of obsessive–compulsive disorder: Have we got it all wrong?

(2013) Vlasios Brakoulias   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

5-HT2C receptor involvement in the control of persistence in the Reinforced Spatial Alternation animal model of obsessive–compulsive disorder

(2013) Vassiliki-Maria Papakosta et al.   BEHAVIOURAL BRAIN RESEARCH

5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option

(2013) Leonhard Lennertz et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism

(2013) Kristian Gaarn du Jardin et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation

(2013) Stefano Pallanti et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Does Extended Release Methylphenidate Help Adults With Hoarding Disorder?

(2013) Carolyn I. Rodriguez et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Hoarding disorder and obsessive–compulsive disorder show different patterns of neural activity during response inhibition

(2013) David F. Tolin et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond

(2012) Naomi A Fineberg et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Quinpirole and 8-OH-DPAT induce compulsive checking behavior in male rats by acting on different functional parts of an OCD neurocircuit

(2012) Ahmad H. Alkhatib et al.   BEHAVIOURAL PHARMACOLOGY

Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder

(2012) Neda Askari et al.   CNS DRUGS

Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review

(2012) Frederike Schirmbeck et al.   Current Neuropharmacology

Regulation of central noradrenergic activity by 5-HT3 receptors located in the locus coeruleus of the rat

(2012) Jorge E. Ortega et al.   NEUROPHARMACOLOGY

Reduction of N-acetylaspartate in the medial prefrontal cortex correlated with symptom severity in obsessive-compulsive disorder: meta-analyses of 1H-MRS studies

(2012) Yuta Aoki et al.   Translational Psychiatry

Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment

(2011) NA Fineberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal models of obsessive compulsive disorder: recent findings and future directions

(2011) Kurt Leroy Hoffman   Expert Opinion on Drug Discovery

Functional Neuroimaging in Obsessive-Compulsive Disorder

(2011) A. Del Casale et al.   NEUROPSYCHOBIOLOGY

Current animal models of obsessive compulsive disorder: an update

(2011) N. Albelda et al.   NEUROSCIENCE

Animal models of obsessive-compulsive disorder: Exploring pharmacology and neural substrates

(2011) Noa Albelda et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior

(2011) Lorenza De Carolis et al.   PSYCHOPHARMACOLOGY

Adding 5-hydroxytryptamine receptor type 3 antagonists may reduce drug-induced nausea in poor insight obsessive-compulsive patients taking off-label doses of selective serotonin reuptake inhibitors: a 52-week follow-up case report

(2011) Michele Fornaro et al.   Annals of General Psychiatry

The Role of Ondansetron in the Treatment of Schizophrenia

(2010) Allison C Bennett et al.   ANNALS OF PHARMACOTHERAPY

Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V

(2010) James F. Leckman et al.   DEPRESSION AND ANXIETY

Should OCD be classified as an anxiety disorder in DSM-V?

(2010) Dan J. Stein et al.   DEPRESSION AND ANXIETY

A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder

(2010) Farhad Soltani et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Increased N-Acetylaspartate/creatine ratio in the medial prefrontal cortex among unmedicated obsessive-compulsive disorder patients

(2010) Qing Fan et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

The role of NMDA receptors in the signal attenuation rat model of obsessive–compulsive disorder

(2010) Noa Albelda et al.   PSYCHOPHARMACOLOGY

Symptom Subtypes of Obsessive–Compulsive Disorder: Are they Relevant for Treatment?

(2009) Vladan Starcevic et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Differences in Neuropsychological Performance Between Subtypes of Obsessive–Compulsive Disorder

(2009) Maja Nedeljkovic et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

(2009) Stefano Pallanti et al.   CNS DRUGS

Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol

(2009) Antonio R. Sa et al.   COMPREHENSIVE PSYCHIATRY

High-dose escitalopram for the treatment of obsessive–compulsive disorder

(2009) Ilan Rabinowitz et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Facilitatory Actions of Serotonin Type 3 Receptors on GABAergic Inhibitory Synaptic Transmission in the Spinal Superficial Dorsal Horn

(2009) Teruyuki Fukushima et al.   JOURNAL OF NEUROPHYSIOLOGY

Efficacy of treatments for patients with obsessive-compulsive disorder: A systematic review

(2009) Yun-Jung Choi   Journal of the American Academy of Nurse Practitioners

Identification of a Domain which Affects Kinetics and Antagonistic Potency of Clozapine at 5-HT3 Receptors

(2009) Gerhard Rammes et al.   PLoS One

Remission of schizophrenia psychosis and strong reduction of obsessive–compulsive disorder after adding clozapine to aripiprazole

(2009) Bart Peters et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The Reinforcing Properties of Salsolinol in the Ventral Tegmental Area: Evidence for Regional Heterogeneity and the Involvement of Serotonin and Dopamine

(2008) Zachary A. Rodd et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern

(2008) K. Mukhopadhaya et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication

(2008) A M Ruscio et al.   MOLECULAR PSYCHIATRY

Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission

(2007) R Exley et al.   BRITISH JOURNAL OF PHARMACOLOGY

Stereotypic behaviour in the deer mouse: Pharmacological validation and relevance for obsessive compulsive disorder

(2007) Schaun Korff et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY